Please Enable JavaScript

www.cablinginstall.comis using a security service for protection against online attacks.
The service requires full JavaScript support in order to view this website.

Please enable JavaScript on your browser and try again.

www.cablinginstall.com is using a security service for protection against online attacks. This process is automatic. You will be redirected once the validation process is complete.

Otsuka Holdings Company ADR (OP: OTSKY )

19.59 UNCHANGED

Streaming Delayed Price Updated: 3:51 PM EDT, May 23, 2024 Add to My Watchlist

Price and Volume

Volume	0
Open	19.59
Bid (Size)	N/A (0)
Ask (Size)	N/A (0)
Prev. Close	19.59
Today's Range	19.59 - 19.59
52wk Range	16.04 - 22.00
Shares Outstanding	N/A
Dividend Yield	N/A

Chart for (: )

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

OTSKY Stock Earnings: Otsuka Holdings Reported Results for Q1 2024

May 17, 2024

Otsuka Holdings just reported results for the first quarter of 2024.

Via InvestorPlace

IGC Pharma Says Cannabinoid-Based Drug Candidate Provides Fast Relief With Fewer Side Effects For Alzheimer's-Associated Agitation

April 16, 2024

IGC Pharma shares encouraging interim data from Phase 2 trial of IGC-AD1 for Alzheimer's agitation. Results suggest significant reduction in agitation with minimal side effects compared to placebo.

Performance

YTD	+5.21%	+5.21%
1 Month	-4.76%	-4.76%
3 Month	+4.70%	+4.70%
6 Month	+3.27%	+3.27%
1 Year	-0.71%	-0.71%

More News

Alzheimer's-Focused Small Cap Firm IGC Pharma Releases Data, Candidate Reduces Agitation Compared To Placebo

March 20, 2024

Regulatory Setback For Medtronic's High Blood Pressure Device - FDA Backed Japanese Firms' Similar Device For Uncontrolled Hypertension

August 24, 2023

Individuals With Uncontrolled Hypertension - FDA Adcomm Panel Just Supported Japanese MedTech's Blood Pressure Treatment Device

August 23, 2023

Akebia's Anemia Drug Disappoints In Mid-Stage COVID-19 Study

August 05, 2022

Why Are Akebia Therapeutics Shares Falling Today?

May 16, 2022

FDA Rejects Akebia Therapeutics' Vadadustat For CKD-Associated Anemia

March 30, 2022

Japan's Otsuka Pharma-Lundbeck Partnered Depression Drug Gets FDA Approval For Alzheimer's Agitation

May 11, 2023

Targeting Autosomal Dominant Polycystic Kidney Disease With Novel Approaches

November 03, 2022

The Daily Biotech Pulse: FDA Wants Omicron-Targeted COVID-19 Boosters, Provention Bio Clears Hits Hurdle For Diabetes Prevention Drug, Oxford Biomedica, AstraZeneca Strike Vaccine Pact

July 01, 2022

Has A Sugar Daddy Emerged In The Psychedelic Drug Industry?

January 31, 2022

Via Talk Markets

4 Pre-Merger SPACs to Buy That Are Poised to Soar

November 16, 2021

Via InvestorPlace

Akebia Therapeutics Stock Jumps as FDA Accepts Vadadustat US Application in CKD-Related Anemia

June 01, 2021

3 Cheap Pharmaceutical Stocks to Grab Now

May 28, 2021

Via Talk Markets

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.